Literature DB >> 24483842

Why does the Iranian national program of screening newborns for G6PD enzyme deficiency miss a large number of affected infants?

Mehrnoush Kosaryan1, Mohammad Reza Mahdavi, Hossein Jalali, Payam Roshan.   

Abstract

PURPOSE: G6PD enzyme deficiency is one of the most prevalent genetic disorders worldwide and it has high incidence rate in Northern provinces of Iran. It was observed that national neonatal screening for G6PD enzyme deficiency fails to detect all affected infants. In order to clarify the cause, this study has been done in Thalassemia Research Center, Sari, Iran.
MATERIALS AND METHODS: This was a diagnostic study. The newborns with parents of Mazandarani origin were enrolled. Cord blood from the placental side was collected and used for decolorization test, quantitative enzyme assay (QEA) and DNA study. A heel-prick sample collected on day 3-5 after birth was used for fluorescent spot test (FST). In male cases, QEA was considered as the gold standard. For females, DNA study was considered as the gold standard. Based on QEA test results, neonates with <20% and 20-60% of mean normal enzyme activity were considered as total deficient and partial deficient, respectively.
RESULTS: A total of 365 neonates (52.3% females and 47.7% males) were studied. According to FST, 13 male newborns had G6PD deficiency. No deficient female was detected. Decolorization test diagnosed 18 male and one female as G6PD deficient newborns. QEA diagnosed 19 males and 28 females with G6PD enzyme deficiency (26 partial, 2 total deficient cases). DNA analysis detected 14 males as hemizygote and 34 females as heterozygote.
CONCLUSION: FST does not have the required sensitivity for newborn screening and QEA is recommended as the preferred method.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24483842     DOI: 10.3109/08880018.2013.871613

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  5 in total

Review 1.  Glucose-6-Phosphate Dehydrogenase Deficiency and Neonatal Hyperbilirubinemia: Insights on Pathophysiology, Diagnosis, and Gene Variants in Disease Heterogeneity.

Authors:  Heng Yang Lee; Azlin Ithnin; Raja Zahratul Azma; Ainoon Othman; Armindo Salvador; Fook Choe Cheah
Journal:  Front Pediatr       Date:  2022-05-24       Impact factor: 3.569

2.  Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests.

Authors:  Germana Bancone; Cindy S Chu; Nongnud Chowwiwat; Raweewan Somsakchaicharoen; Pornpimon Wilaisrisak; Prakaykaew Charunwatthana; Pooja Bansil; Sarah McGray; Gonzalo J Domingo; François H Nosten
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

3.  Screening for glucose-6-phosphate dehydrogenase deficiency in neonates: a comparison between cord and peripheral blood samples.

Authors:  Saif AlSaif; Ma Bella Ponferrada; Khalid AlKhairy; Khalil AlTawil; Adel Sallam; Ibrahim Ahmed; Mohammed Khawaji; Khalid AlHathlol; Beverly Baylon; Ahmed AlSuhaibani; Mohammed AlBalwi
Journal:  BMC Pediatr       Date:  2017-07-11       Impact factor: 2.125

4.  Diagnostic performances of the fluorescent spot test for G6PD deficiency in newborns along the Thailand-Myanmar border: A cohort study.

Authors:  Laurence Thielemans; Gornpan Gornsawun; Borimas Hanboonkunupakarn; Moo Kho Paw; Pen Porn; Paw Khu Moo; Bart Van Overmeire; Stephane Proux; François Nosten; Rose McGready; Verena I Carrara; Germana Bancone
Journal:  Wellcome Open Res       Date:  2018-01-02

5.  Comparison of Spectrophotometry, Chromate Inhibition, and Cytofluorometry Versus Gene Sequencing for Detection of Heterozygously Glucose-6-Phosphate Dehydrogenase-Deficient Females.

Authors:  Anna L Peters; Martijn Veldthuis; Karin van Leeuwen; Patrick M M Bossuyt; Alexander P J Vlaar; Robin van Bruggen; Dirk de Korte; Cornelis J F Van Noorden; Rob van Zwieten
Journal:  J Histochem Cytochem       Date:  2017-09-13       Impact factor: 2.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.